1. Recombinant Human Factor VIIa for Alveolar Hemorrhage Following Allogeneic Stem Cell Transplantation 
Jason M. Elinoff, Ulas Bagci, Brad Moriyama, Jennifer L. Dreiling, Brent Foster, Nicole J. Gormley, Rachel B. Salit, Rongman Cai, Junfeng Sun, Andrea Beri, Debra J. Reda, Farhad Fakhrejahani, Minoo Battiwalla, Kristin Baird, Jennifer M. Cuellar-Rodriguez, Elizabeth M. Kang, Stephen Z. Pavletic, Dan H. Fowler, A. John Barrett, Jay N. Lozier, David E. Kleiner, Daniel J. Mollura, Richard W. Childs, Anthony F. Suffredini 
Biology of Blood and Marrow Transplantation 
Volume 20, Issue 7, Pages (July 2014)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
Survival in the rFVIIa and conventional therapy groups. Shown are Kaplan-Meier survival curves depicting outcomes in the first 180 days after onset of the initial AH episode. The solid line represents the rFVIIa group; the dashed line, the conventional therapy group.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

3. Figure 2
Extent of radiographic pulmonary pathology at the onset of AH. Shown are representative surface renderings of pulmonary parenchymal pathology at the onset of AH from 5 different patients in the rFVIIa group. (A) Patient 8; 8%. (B) Patient 21; 20%. (C) Patient 5; 25%. (D) Patient 13; 37%. (E) Patient 11; 47%. Total lung volume is outlined in blue, and pathological areas are highlighted in light green.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

4. Figure 3
Effect of rFVIIa therapy on ICU length of stay (LOS), duration of mechanical ventilation (MV), resolution of AH, and duration of supplemental oxygen use in the rFVIIa and conventional therapy groups. There was no between-group difference in ICU length of stay due to AH (episodes included in analysis: rFVIIa, 23 of 43; conventional therapy, 8 of 14; P = .63), duration of mechanical ventilation due to AH (rFVIIa, 25 of 43; conventional therapy, 7 of 14; P = .89), time to resolution of AH (rFVIIa, 30 of 43; conventional therapy, 10 of 14; P = .50), or duration of supplemental oxygen use from the onset of the initial episode of AH (rFVIIa, 23 of 23; conventional therapy, 14 of 14; P = .55).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

5. Figure 4
Survival in patients with DAH and IAH. Shown are Kaplan-Meier survival curves depicting outcomes in the first 180 days after onset of the initial episode of AH in patients with DAH (A) and patients with IAH (B). The solid line represents the rFVIIa group; the dashed line, the conventional therapy group.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

6. Figure 5
Autopsy sections of representative lung histopathology. (A) Hematoxylin and eosin staining showing accumulation of red blood cells, fibrin, and hemosiderin-laden macrophages in alveolar spaces. (Original magnification, 20×.) (B) Iron staining highlighting hemosiderin-laden macrophages within the alveolar and interstitial spaces. (Original magnification, 20×.) (C and D) C4d staining highlighting predominantly large-caliber vessels (C) and hyaline membranes (D). (Original magnification, 20×.)
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

7. Figure S1
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

8. Figure S2
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

9. Figure S3
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

10. Figure S4
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

11. Figure S5
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

12. Figure S6
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions